|
|
Blood, 15 October 2006, Vol. 108, No. 8, pp. 2874-2880.
Prepublished online as a Blood First Edition Paper on June 27, 2006; DOI 10.1182/blood-2006-03-011791.
 Previous Article | Table of Contents | Next Article 
TRANSPLANTATION
Marked increased risk of Epstein-Barr virus-related complications with the addition of antithymocyte globulin to a nonmyeloablative conditioning prior to unrelated umbilical cord blood transplantation
Claudio G. Brunstein,
Daniel J. Weisdorf,
Todd DeFor,
Juliet N. Barker,
Jakub Tolar,
Jo-Anne H. van Burik, and
John E. Wagner
From the Blood and Marrow Transplant Program, Departments of Medicine and Pediatrics, University of Minnesota, Minneapolis.
Umbilical cord blood (UCB) is increasingly used as an alternative source of hematopoietic stem cells for transplantation for patients who lack a suitable sibling donor. Despite concerns about a possible increased risk of Epstein-Barr virus (EBV) posttransplantation lymphoproliferative disorder (PTLD) after UCB transplantation, early reports documented rates of PTLD comparable to those reported after HLA-matched unrelated marrow myeloablative (MA) transplantations. To further investigate the incidence of EBV PTLD after UCB transplantation and potential risk factors, we evaluated the incidence of EBV-related complications in 335 patients undergoing UCB transplantation with an MA or nonmyeloablative (NMA) preparative regimen. The incidence of EBV-related complications was a 4.5% overall, 3.3% for MA transplantations, and 7% for NMA transplantations. However, the incidence of EBV-related complications was significantly higher in a subset of patients treated with an NMA preparative regimen that included antithymocyte globulin (ATG) versus those that did not (21% vs 2%; P < .01). Nine of 11 patients who developed EBV PTLD were treated with rituximab (anti-CD20 antibody), with the 5 responders being alive and disease free at a median of 26 months. Use of ATG in recipients of an NMA preparative regimen warrants close monitoring for evidence of EBV reactivation and potentially preemptive therapy with rituximab.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
R. W. Childs and C. S. Zerbe
Expanding multiviral reactive T cells from cord blood
Blood,
August 27, 2009;
114(9):
1725 - 1726.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. J. Hanley, C. R. Y. Cruz, B. Savoldo, A. M. Leen, M. Stanojevic, M. Khalil, W. Decker, J. J. Molldrem, H. Liu, A. P. Gee, et al.
Functionally active virus-specific T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes
Blood,
August 27, 2009;
114(9):
1958 - 1967.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Robin, S. Marque-Juillet, C. Scieux, R. P. de Latour, C. Ferry, V. Rocha, J.-M. Molina, A. Bergeron, A. Devergie, E. Gluckman, et al.
Disseminated adenovirus infections after allogeneic hematopoietic stem cell transplantation: incidence, risk factors and outcome
Haematologica,
September 1, 2007;
92(9):
1254 - 1257.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Juvonen, S. Aalto, J. Tarkkanen, L. Volin, K. Hedman, and T. Ruutu
Retrospective evaluation of serum Epstein Barr virus DNA levels in 406 allogeneic stem cell transplant patients
Haematologica,
June 1, 2007;
92(6):
819 - 825.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Scheinberg, S. H. Fischer, L. Li, O. Nunez, C. O. Wu, E. M. Sloand, J. I. Cohen, N. S. Young, and A. John Barrett
Distinct EBV and CMV reactivation patterns following antibody-based immunosuppressive regimens in patients with severe aplastic anemia
Blood,
April 15, 2007;
109(8):
3219 - 3224.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
